NFKB1 and ependymoma: Interestingly, blocking the NF-KB pathway by proteasome inhibitors may have a beneficial therapeutic effect in the ependymoma RELA-fusion molecular subgroup, and marizomib is being investigated for this purpose (ClinicalTrials.gov Identifier: NCT03727841).